Rifampin contraindications: Difference between revisions
(Created page with "__NOTOC__ {{Rifampin }} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RIFADIN (RIFAMPIN) CAPSULE RIFADIN IV (RIFA...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Contraindications== | |||
RIFADIN is contraindicated in patients with a history of hypersensitivity to rifampin or any of the components, or to any of the rifamycins. (See Warnings.) | |||
Rifampin is contraindicated in patients who are also receiving [[ritonavir]]-boosted [[saquinavir]] due to an increased risk of severe hepatocellular toxicity. (See Precautions, Drug Interactions.) | |||
Rifampin is contraindicated in patients who are also receiving [[atazanavir]], [[darunavir]], [[fosamprenavir]], [[saquinavir]], or [[tipranavir]] due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in loss of antiviral efficacy and/or development of viral resistance. | |||
Latest revision as of 23:13, 5 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Contraindications
RIFADIN is contraindicated in patients with a history of hypersensitivity to rifampin or any of the components, or to any of the rifamycins. (See Warnings.)
Rifampin is contraindicated in patients who are also receiving ritonavir-boosted saquinavir due to an increased risk of severe hepatocellular toxicity. (See Precautions, Drug Interactions.)
Rifampin is contraindicated in patients who are also receiving atazanavir, darunavir, fosamprenavir, saquinavir, or tipranavir due to the potential of rifampin to substantially decrease plasma concentrations of these antiviral drugs, which may result in loss of antiviral efficacy and/or development of viral resistance.
References
Adapted from the FDA Package Insert.